Go to content

CCRM Nordic Welcomes Lars-Johan Cederbrant to Its Board of Directors

Date: 17 July 2025

Place: Gothenburg

CCRM Nordic Welcomes Lars-Johan Cederbrant to Its Board of Directors

CCRM Nordic is pleased to announce the appointment of Lars-Johan Cederbrant to its Board of Directors. Lars-Johan currently serves as Chief Financial Officer (CFO) of AstraZeneca AB, the Swedish Hub of AstraZeneca, and is a member of AstraZeneca’s global Finance Senior Management Team and Sweden Leadership Team.

With a distinguished career spanning leadership roles across AstraZeneca’s corporate finance functions globally, Lars-Johan brings deep expertise in biopharma finance and strategic development. His prior experience also includes CFO positions outside AstraZeneca, such as serving as CFO for a company listed on NASDAQ Stockholm, as well as working as a management consultant.

“I’ve been working in the field of life science for a long time, and I very much look forward to supporting CCRM Nordic in their endeavour to build a leading hub and to support the commercialization of ATMPs,” said Lars-Johan Cederbrant.

CCRM Nordic’s collaborative consortium model thrives on the contributions of industry leaders who bring broad perspectives and powerful networks to the table. With the addition of Lars-Johan Cederbrant, CCRM Nordic further strengthens its ability to advance capabilities and deliver impact in the rapidly evolving ATMP landscape.

“We’re confident that Lars-Johan’s deep experience in the biopharma world and strong financial expertise will be a huge asset as we continue to grow and support innovation in the ATMP space,” said Jan Nilsson, Chairman of the Board at CCRM Nordic. “We all look forward to what lies ahead with him on the team.”

About CCRM Nordic:

CCRM Nordic is a leading organization dedicated to advancing research, development, and commercialization of advanced therapy medicinal products (ATMPs). With a focus on innovation and collaboration, CCRM Nordic strives to accelerate the translation of scientific discoveries into tangible therapies that address unmet medical needs.

Visit ccrmnordic.se

About CCRM:

CCRM is a global, public-private partnership headquartered in Canada, established with seed funding provided by the Government of Canada, the Province of Ontario, and leading academic and industry partners. CCRM supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of researchers, leading companies, investors and entrepreneurs, CCRM accelerates the translation of scientific discovery into new companies and marketable products for patients, with specialized teams, dedicated funding, and unique infrastructure. In 2022, CCRM established OmniaBio Inc., a pre-clinical to commercial-stage CDMO for manufacturing gene-modified cells and viral vectors for cell and gene therapies. CCRM is hosted by the University of Toronto. Visit at ccrm.ca

How can we assist you?

Talk to us